Navigation Links
XSera Rapid HIV-1/2 Antibody Controls

ProductsXSera Rapid HIV-1/2 Antibody Controls
Company RNA Medical
Item XSera Rapid HIV-1/2 Antibody Controls
Features 
  • Liquid-ready (no reconstitution required)
  • Evaluated on FDA cleared rapid HIV kits
  • 60 day open-bottle storage (room temperature)
  • Heat inactivated human plasma with antibodies to HIV-1 or HIV-2
  • Convenient plastic screw top vial
Description Xsera Rapid HIV-1/2 Antibody Controls are unassayed positive and negative quality control materials used for monitoring the performance of qualitative rapid HIV-1 and HIV-2 test kits.
Info RNA Medical
Customer Service: (800) 533-6162
Web site: http://www.rnamedical.com/

Related medicine products :

1. RapidLab 248 Blood Gas Analyzer
2. Rapidlab 800 System
3. Rapidlab 348 Blood Gas Analyzer
4. Rapidpoint 400
5. Rapidlink Critical Care Information Management System
6. IDS Rapid NF Plus
7. IDS Rapid NH
8. IDS Rapid One
9. IDS Rapid SS/u
10. IDS Rapid STR
11. IDS Rapid Yeast Plus
Other Medicine News:Health News:Bradmer announces 2008 fourth quarter and fiscal year operational and financial results 2Health News:Bradmer announces 2008 fourth quarter and fiscal year operational and financial results 3Health News:Bradmer announces 2008 fourth quarter and fiscal year operational and financial results 4Health News:Bradmer announces 2008 fourth quarter and fiscal year operational and financial results 5Health News:Bradmer announces 2008 fourth quarter and fiscal year operational and financial results 6Health News:Bradmer announces 2008 fourth quarter and fiscal year operational and financial results 7Health News:Bradmer announces 2008 fourth quarter and fiscal year operational and financial results 8Health News:Bradmer announces 2008 fourth quarter and fiscal year operational and financial results 9Health News:Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer 2Health News:Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer 3Health News:Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer 4Health News:Virus evolution topic of Darwin talk at UH April 2 2Health News:Study Casts Doubt on Influential Hospital Safety Survey 2Health News:Study Casts Doubt on Influential Hospital Safety Survey 3Health News:Novavax Reports Fourth Quarter and 2008 Year-End Financial Results 2Health News:Novavax Reports Fourth Quarter and 2008 Year-End Financial Results 3Health News:Novavax Reports Fourth Quarter and 2008 Year-End Financial Results 4Health News:Novavax Reports Fourth Quarter and 2008 Year-End Financial Results 5Health News:Novavax Reports Fourth Quarter and 2008 Year-End Financial Results 6Health News:Novavax Reports Fourth Quarter and 2008 Year-End Financial Results 7Health News:Novavax Reports Fourth Quarter and 2008 Year-End Financial Results 8Health News:Novavax Reports Fourth Quarter and 2008 Year-End Financial Results 9Health News:National Council on Disability Calls for New Federal Approach to Disability Policy 2
Breaking Medicine Technology:Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine 2Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 2Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 3Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 4Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6Donor Stem Cell Transplant Best For Acute Myeloid Leukemia 48368 1Donor Stem Cell Transplant Best For Acute Myeloid Leukemia 48368 2Donor Stem Cell Transplant Best For Acute Myeloid Leukemia 48368 3Health care issues lead latest Arizona State University Southwest Poll 48364 1Health care issues lead latest Arizona State University Southwest Poll 48364 2Health care issues lead latest Arizona State University Southwest Poll 48364 3Health care issues lead latest Arizona State University Southwest Poll 48364 4Story tips from the Department of Energys Oak Ridge National Laboratory June 2009 8774 1Story tips from the Department of Energys Oak Ridge National Laboratory June 2009 8774 2Story tips from the Department of Energys Oak Ridge National Laboratory June 2009 8774 3